Literature DB >> 18855733

Multi-faceted aspects of gamma-hydroxybutyric acid: a neurotransmitter, therapeutic agent and drug of abuse.

M Paola Castelli1.   

Abstract

Gamma hydroxybutyric acid (GHB), an endogenous constituent of the mammalian brain, acts as i) a neurotransmitter or neuromodulator, ii) a medicine used for the treatment of narcolepsy and alcoholism, and iii) a drug illicitly used for its psychotropic effects. GHB is thought to act as a specific GHB receptor agonist as well as a weak gamma-aminobutyric acid type B (GABA(B)) receptor agonist. Here, I review the in vivo and in vitro pharmacological properties of GHB and its interaction with GHB and GABA(B) receptors. When exogenously administered, GHB is rapidly absorbed, crosses the blood-brain barrier, penetrates into the brain and exerts a number of pharmacological effects including anxiolysis, sedation/hypnosis and anesthesia. Due to its effects on the central nervous system, GHB has been used for the treatment of narcolepsy and as an anesthetic adjuvant. More recently, a role for GHB in the pharmacotherapy of alcohol dependence has been described. In this review, I also focus on the abuse liability and reinforcing properties of GHB in humans and laboratory animals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855733     DOI: 10.2174/138955708786141025

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  3 in total

1.  Introduction to the special issue "Pharmacotherapies for the treatment of alcohol abuse and dependence" and a summary of patents targeting other neurotransmitter systems.

Authors:  Richard L Bell; Kelle M Franklin; Sheketha R Hauser; Feng C Zhou
Journal:  Recent Pat CNS Drug Discov       Date:  2012-08

2.  Analysis of electrical brain waves in neurotoxicology: γ-hydroxybutyrate.

Authors:  Z K Binienda; M A Beaudoin; B T Thorn; S F Ali
Journal:  Curr Neuropharmacol       Date:  2011-03       Impact factor: 7.363

3.  γ-Hydroxybutyrate does not mediate glucose inhibition of glucagon secretion.

Authors:  Qian Yu; Bao Khanh Lai; Parvin Ahooghalandari; Anders Helander; Erik Gylfe; Patrick Gilon; Anders Tengholm
Journal:  J Biol Chem       Date:  2020-03-10       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.